Last reviewed · How we verify
Placebo.
Placebo. is a Small molecule drug developed by University Hospital, Bordeaux. It is currently FDA-approved for Subjective symptom relief in clinical research and therapeutic contexts (pain, nausea, fatigue).
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, rather than through a pharmacologically active ingredient.
Placebo is a control intervention used in clinical trials to compare the effects of other treatments. It has been used as a control in studies for conditions such as hypercholesterolemia, Alzheimer's Disease, and Vitamin D Deficiency, among others.
At a glance
| Generic name | Placebo. |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Modality | Small molecule |
| Therapeutic area | Multiple (context-dependent) |
| Phase | FDA-approved |
Mechanism of action
Placebo works via psychological and neurobiological mechanisms including expectation, conditioning, and activation of endogenous pain-relief and reward pathways. The effect is particularly pronounced in conditions with subjective symptom components such as pain, nausea, and fatigue. While placebo has no direct molecular target, it can produce measurable physiological changes through mind-body interactions.
Approved indications
- Subjective symptom relief in clinical research and therapeutic contexts (pain, nausea, fatigue)
Common side effects
- Nocebo effects (adverse expectations)
- Delayed treatment of underlying condition if used as sole therapy
Key clinical trials
- Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease (NA)
- Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure (NA)
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases (PHASE3)
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo. CI brief — competitive landscape report
- Placebo. updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI
Frequently asked questions about Placebo.
What is Placebo.?
How does Placebo. work?
What is Placebo. used for?
Who makes Placebo.?
What development phase is Placebo. in?
What are the side effects of Placebo.?
Related
- Manufacturer: University Hospital, Bordeaux — full pipeline
- Therapeutic area: All drugs in Multiple (context-dependent)
- Indication: Drugs for Subjective symptom relief in clinical research and therapeutic contexts (pain, nausea, fatigue)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing